Feed Preview

Tau Antibody Therapy in Neurodegenerative Diseases

Tau Antibody Therapy in Neurodegenerative Diseases diagram by undefined

Tau vaccination and administration of anti-tau antibodies can prevent pathology and cognitive impairment in transgenic mouse models of tauopathy, suggesting that therapies which increase anti-tau antibodies might slow the development and/or progression of tauopathies including Alzheimer's disease. Here is the latest research.

Top 20 most recent papers
bioRxiv

Screening of Tau Protein Kinase Inhibitors in a Tauopathy-relevant cell-based model of Tau Hyperphosphorylation and Oligomerization

bioRxivOctober 28, 2019
Hamad YadikarKevin Ka Wan Wang
2
Scientific Reports

A MultiTEP platform-based epitope vaccine targeting the phosphatase activating domain (PAD) of tau: therapeutic efficacy in PS19 mice

Scientific ReportsOctober 29, 2019
Armine HovakimyanHayk Davtyan
5
8
Brain : a Journal of Neurology

PET-detectable tau pathology correlates with long-term neuropsychiatric outcomes in patients with traumatic brain injury

Brain : a Journal of NeurologySeptember 2, 2019
Keisuke TakahataMakoto Higuchi
52
1
2
10
Molecular Neurodegeneration

Targeting tauopathy with engineered tau-degrading intrabodies

Molecular NeurodegenerationOctober 22, 2019
Gilbert GallardoDavid. M. Holtzman
5
1
Alzheimer's & Dementia : the Journal of the Alzheimer's Association

Prediction of Alzheimer's disease diagnosis within 14 years through Aβ misfolding in blood plasma compared to APOE4 status, and other risk factors

Alzheimer's & Dementia : the Journal of the Alzheimer's AssociationOctober 11, 2019
Hannah StockerHermann Brenner
12
14
1
Alzheimer's & Dementia : the Journal of the Alzheimer's Association

Effects of single and combined immunotherapy approach targeting amyloid β protein and α-synuclein in a dementia with Lewy bodies-like model

Alzheimer's & Dementia : the Journal of the Alzheimer's AssociationAugust 6, 2019
Markus MandlerRobert A. Rissman
5
1
1
20
Artificial Cells, Nanomedicine, and Biotechnology

Sublingual immunotherapy of atopic dermatitis in mite-sensitized patients: a multi-centre, randomized, double-blind, placebo-controlled study

Artificial Cells, Nanomedicine, and BiotechnologyAugust 23, 2019
Lun-Fei LiuMin Jia Zheng
Clinical Reviews in Allergy & Immunology

Systemic Amyloidosis: a Contemporary Overview

Clinical Reviews in Allergy & ImmunologyAugust 2, 2019
Vittorio D'AguannoAntonio Greco
1
9
Acta Neuropathologica

From the prion-like propagation hypothesis to therapeutic strategies of anti-tau immunotherapy

Acta NeuropathologicaNovember 4, 2019
Morvane ColinLuc BUEE
8
2
Brain : a Journal of Neurology

Could changing the course of Alzheimer's disease pathology with immunotherapy prevent dementia?

Brain : a Journal of NeurologyJuly 1, 2019
Cassia Rose Overk, Eliezer Masliah
45
1
1
10
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology

Characteristics of venom allergy at initial evaluation: Is fire ant hypersensitivity similar to flying Hymenoptera?

Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & ImmunologySeptember 3, 2019
Sofia SzariKevin M White
Acta Neuropathologica Communications

Therapeutic antibody targeting microtubule-binding domain prevents neuronal internalization of extracellular tau via masking neuron surface proteoglycans

Acta Neuropathologica CommunicationsAugust 7, 2019
Petronela WeisovaMichal Novak
2
8
Research : a Science Partner Journal

Promising Results from Alzheimer's Disease Passive Immunotherapy Support the Development of a Preventive Vaccine

Research : a Science Partner JournalMay 19, 2019
Dante J Marciani
2
2
8
CNS Drugs

Emerging Developments in Targeting Proteotoxicity in Neurodegenerative Diseases

CNS DrugsAugust 16, 2019
Luke McAlaryNeil R. Cashman
5
1
6
Journal of Korean Medical Science

Targeted Downregulation of kdm4a Ameliorates Tau-engendered Defects in Drosophila melanogaster

Journal of Korean Medical ScienceAugust 23, 2019
Sung Yeon ParkYang-Sook Chun
4
1
1
Expert Opinion on Drug Discovery

How plausible is an Alzheimer's disease vaccine?

Expert Opinion on Drug DiscoverySeptember 17, 2019
Ramón Cacabelos
1
Current Alzheimer Research

Active Amyloid-β Vaccination Results in Epigenetic Changes in the Hippocampus of an Alzheimer's Disease-Like Mouse Model

Current Alzheimer ResearchAugust 27, 2019
Roy LardenoijeCynthia A Lemere
2
1
5
Human Gene Therapy

Anti-phospho-tau Gene Therapy for Chronic Traumatic Encephalopathy

Human Gene TherapyOctober 14, 2019
Chester Bittencourt SacramentoRonald G. Crystal
1
1
Journal of Alzheimer's Disease : JAD

Classification of Clinically Diagnosed Alzheimer's Disease Associated with Diabetes Based on Amyloid and Tau PET Results

Journal of Alzheimer's Disease : JADJuly 23, 2019
Naoto TakenoshitaHaruo Hanyu
1
1
3
Journal of Neuropathology and Experimental Neurology

Tau Phosphorylation and Aggregation in the Developing Human Brain

Journal of Neuropathology and Experimental NeurologySeptember 11, 2019
Marco M HeftiJohn F Crary
1

See more papers from this feed

Related Feeds

ALS

Amyotrophic Lateral Sclerosis (ALS), also known as motor neuron disease, is associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS here.

ALS & FTD: TDP-43

ALS shares with a considerable proportion of FTD cases the same neuropathological substrate, namely, inclusions of abnormally phosphorylated protein tdp-43 (ptdp-43). Here are the latest discoveries pertaining to ptdp-43 and these diseases.

ALS - Pathogenic Mechanisms

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating pathogenic mechanisms that underlie this genetically heterogeneous disorder.

ALS - Phenotypes

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating phenotypes associated with this genetically heterogeneous disorder.

ALS: Genetics

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. ALS is a genetically heterogeneous disorder with several causative genes. Here are the latest discoveries pertaining to the genetics of this disease.

ALS: Prions

Prions are misfolded proteins which characterize several fatal neurodegenerative diseases. Prion-like mechanisms are associated with the pathogenesis of Amyotrophic Lateral Sclerosis (ALS). Here are the latest discoveries pertaining to this disease.

ALS: Stress Granules

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease characterized by cytoplasmic protein aggregates within motor neurons. TDP-43 is an ALS-linked protein that is known to regulate splicing and storage of specific mRNAs into stress granules, which have been implicated in formation of ALS protein aggregates. Here is the latest research.

ALS: Therapies

Amyotrophic Lateral Sclerosis (ALS), also known as motor neuron disease, is associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS therapies here.

ALS: Transposon de-silencing

Transposon silencing is a form of transcriptional gene silencing. These gene silencing mechanisms are impaired in Amyotrophic lateral sclerosis (ALS). Here are the latest discoveries pertaining to transposon silencing and this disease.

Age-related Dementia

Age-related dementia (Alzheimer's disease) results from the destructive impact of the pulse on cerebral vasculature. Evidence is reviewed that the neuropathology of the dementia is caused by the breakdown of small cerebral vessels (silent microbleeds), that the microbleeds result from pulse-induced damage to the cerebral vessels, and that pulse becomes increasingly destructive with age, because of the age-related stiffening of the aorta and great arteries, which causes an increase in the intensity of the pressure pulse. Discover the latest research on age-related dementia here.

© 2019 Meta ULC. All rights reserved
/feed-previews/tau-antibody-therapy-in-neurodegenerative/d55e613b-55f6-4469-92e8-bd3a5ea2c43f